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Abstract:  
Background & Aims: Colonic strictures complicate inflammatory bowel disease (IBD) and 
often lead to surgical resection to prevent dysplasia or cancer. We assessed the frequency of 
dysplasia and cancer among IBD patients undergoing resection of a colorectal stricture. 
Methods: We analyzed data from the Groupe d’études et thérapeutiques des affections 
inflammatoires du tube digestif study. This was a nationwide retrospective study of 12,013 
patients with IBD in France who underwent surgery for strictures at 16 centers, from August 
1992 through January 2014 (293 patients for a colonic stricture, 248 patients with Crohn’s 
disease, 51% male, median age at stricture diagnosis was 38 y). Participants had no 
preoperative evidence of dysplasia or cancer. We collected clinical, endoscopic, surgical, and 
pathology data and information on outcomes.  
Results: When patients were diagnosed with strictures, they had IBD for a median time of 8 y 
(3−14 y). The strictures were a median length of 6 cm (4−10 cm) and caused symptoms in 
70% of patients. Of patients with Crohn’s disease, 3 were found to have low-grade dysplasia 
(1%), 1 was found to have high-grade dysplasia (0.4%), and 2 were found to have cancer 
(0.8%). Of patients with ulcerative colitis, 1 had low-grade dysplasia (2%), 1 had high-grade 
dysplasia (2%), and 2 had cancer (5%). All patients with dysplasia or cancer received curative 
surgery, except 1 who died of colorectal cancer during the follow-up period. No active disease 
at time of surgery was the only factor associated with dysplasia or cancer at the stricture site 
(odds ratio, 4.86; 95% confidence interval, 1.11–21.27; P=.036). 
Conclusion: In a retrospective study of patients with IBD undergoing surgery for colonic 
strictures, 3.5% were found to have dysplasia or cancer. These findings can be used to guide 
management of patients with IBD and colonic strictures.  
  
KEY WORDS: GETAID study, CD, UC, colon cancer risk factors, carcinogenesis 
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Inflammatory bowel diseases (IBD) are chronic progressive and destructive 
conditions (1, 2). Colorectal strictures may occur in both Crohn’s disease (CD) and 
ulcerative colitis (UC) (3, 4, 5). Old referral centers studies, most of them published 
before the 90’s, reported a prevalence of colonic stricture in UC ranging from 1.5% to 
11% (6, 7, 8, 9, 10, 11) and from 10 to 14% in CD (12, 13). The occurrence of colonic 
strictures raises concerns about the risk of dysplasia/cancer in IBD patients. The risk 
of dysplasia or cancer associated with colonic strictures in UC varies among studies 
and ranged from 0% to 86% (7, 8, 9, 10, 14), while it is poorly known in CD (12). All 
these studies were characterized by a low number of included patients, the largest 
one included 52 strictures in UC (9) and 132 in CD patients (12), and little information 
on clinical and pathological findings levels, none of these studies had detailed 
information about dysplasia grade or cancer” (7, 8, 9, 12, 14). In two studies, factors 
with dysplasia or cancer in IBD patients with colonic strictures were appearance late 
in the course of the disease or at older age, proximal colonic location, and 
symptomatic strictures (8,12). Diagnosing dysplasia/cancer on endoscopic biopsies 
is a challenge in clinical practice and the absence of dysplasia or cancer on 
endoscopic biopsies cannot formally rule out the presence of dysplasia/cancer (10). 
Hence, the fear of missed colorectal cancer complicating colonic stricture leads 
frequently to colonic resection in these IBD patients.  
The aim of this study was therefore to assess the risk of dysplasia or cancer among 
IBD patients undergoing intestinal resection for a colorectal stricture without 
dysplasia or cancer known at the time of surgery in a nationwide retrospective cohort 
study from the “Groupe d’études et thérapeutiques des affections inflammatoires du 
tube digestif”  (GETAID). 
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Methods 
Identification of cases 
All the 42 members of the GETAID, in France, Belgium and Netherlands were invited 
to participle in this study. Only centers having access to a clinical, surgical or 
pathological database including all consecutive adult patients operated on for IBD 
could participate. Inclusion criteria were: (1) adults (18 years old) CD, UC or 
unclassified colitis patients (IBD-U), (2) operated on for colonic stricture, (3) no 
colonic dysplasia or cancer known at the time of surgery (pre-operative endoscopic 
colonic biopsies free of dysplasia/cancer). Stricture was defined as a fixed, localized 
colonic narrowing. Anastomotic strictures and obvious polypoid lesions producing 
narrowing of the lumen were excluded. 
Data collection  
Clinical, surgical and pathological data were extracted from patient’s hospital medical 
records retrospectively, using a standardized questionnaire that was developed 
specifically for this study. The following clinical data were collected: age, sex, date of 
IBD diagnosis, familial history of IBD or colorectal cancer, personal history of 
colorectal cancer/dysplasia or colonic surgery, IBD phenotype and behaviour 
according to the Montreal classification (15), disease activity at time of surgery based 
on physicians’ judgment, previous exposure to IBD-related medications (5-
aminosalicylate, azathioprine, and anti-TNF). The following information on colonic 
stricture was collected: date of diagnosis, location, length, symptomatic character, 
passable with the endoscope. We also collected data on surgery: date of surgery, 
type of surgery (partial colectomy, total colectomy, coloprotectomy). Presence of 
dysplasia (low grade or high grade dysplasia) or cancer (histological description) was 
also recorded.  

Statistical analysis 
Continuous variables were calculated as medians with interquartile ranges (Q1-Q3). 
Qualitative variables were given as frequencies and percentages. Comparison of 
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frequencies was performed using the X2 or Mann Withney test. Associated factors to 
dysplasia or cancer were searched by using logistic regression in univariate model. 
Parameters with p value < 0.1 in univariate analysis were introduced in multivariable 
regression. Data were analyzed with SAS software V.9.3 (SAS, Chicago, Illinois, 
USA). Statistical significance was considered p0.05. 

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Results 
Study population  
By selecting only GETAID centres having a database enrolling consecutive IBD 
patients, 12 013 IBD patients operated on for IBD in 16 GETAID centres between 
August 1992 and January 2014 were screened. We identified 293 (2.3%) patients 
operated on for a colonic stricture with pre-operative endoscopic colonic biopsies free 
of dysplasia/cancer, including 248 CD, 39 UC, and 6 IBD-U patients (flow chart figure 
1).  Note that we evaluated in one center the number of patients with a preoperative 
diagnosis of dysplasia or cancer on colonic stricture. In the center of Amiens, 0.6% of 
patients operated on for CD and 2.5% of patients operated on for UC were operated 
on for colonic stricture with a preoperative diagnosis of dysplasia or cancer.  
Characteristics of the study population are listed in Table 1. Among the 293 patients 
operated on for a colonic stricture with pre-operative endoscopic colonic biopsies free 
of dysplasia/cancer, 51% were males, 42% had CD and 64% UC (CD versus UC; 
p=0.012). Familial history of IBD was present in 16% of patients, and respectively 
4.8% and 9% of patients had a personal or familial history of colonic dysplasia/CRC.  
CD phenotype according to the Montreal Classification was pure colonic disease (L2) 
in 56% and ileocolonic disease (L3) in 44% of cases. History of perianal disease was 
reported in 32% of patients. In UC, 2% of patients had proctitis (E1), 34% left-sided 
colitis, and 64% pancolitis (E3). 68% of CD patients had a penetrating behaviour 
associated to strictures. 13% of the overall IBD population experienced a prior 
colonic resection. Previous exposition to 5-aminosalicylates, azathioprine and anti-
TNF were observed in respectively 65%, 68% and 50% of CD patients, and 86%, 
48% and 36% of UC patients.  
At stricture diagnosis, UC patients (55 [41-65]) years) were significantly older than 
CD (36 [26-48] years) (p=0.003). The median disease duration at stricture diagnosis 
was 6 [1-12] years in UC and 8 [3-14] years in CD. 
Strictures characteristics 
Strictures characteristics are detailed in Table 2. All patients underwent preoperative 
colonoscopy. Strictures were not passable with the endoscope in 64% of cases. 
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Strictures presented a median length of 6 cm [4-10], and were symptomatic in 70% of 
patients, with no significant difference between CD and UC. In CD, location of 
strictures was right colon in 16%, transverse colon in 14%, left colon in 64% and 
rectum in 6% of patients. In UC, strictures location was right colon in 6%, transverse 
colon in 13%, left colon in 62%, and rectum in 19% of patients. 
Surgery  

Median disease duration at surgery was 8.8 [4.2-15.7] years without significant 
difference between CD and UC. Median stricture duration at surgery was shorter in 
UC (3 [0.6-9.6] months) than in CD 6.3 [1.6-20] months) (p=0.08). Active disease at 
time of surgery was reported in 87% of CD and 64% of U  patients. Surgical 
procedure was significantly different between CD and UC (p<0.001): partial 
colectomy, total colectomy and coloprotectomy were performed respectively in 79%, 
19% and 10% of CD patients versus 18%, 28% and 54% of UC patients.  

Risk of dysplasia and cancer complicating colonic strictures  
Dysplasia or cancer was observed in 10 (3.5%) patients with IBD, 6 (2.4%) CD 
patients, and 4 (10%) UC patients (Table 3). Cancer was observed in 2 (0.8%) CD 
patients and 2 (5%) UC patients.  High-grade dysplasia (HGD) and low-grade 
dysplasia (LGD) were observed in respectively one (0.4%) and 3 (1.2%) CD patients, 
and one (2.5%) and one (2.5%) UC patients.   
Clinical characteristics of these patients are detailed in Table 4. In UC, all cancer or 
dysplasia occurred in patients  59 years, with a long disease duration ( 15 years) 
for all patients. Clinical presentation in CD was different. Dysplasia or cancer 
occurred in patients with an age ranging from 20 to 70 years, and disease duration 
ranged between 0 and 32 years. 60% of strictures with dysplasia or cancer were 
located in descendant colon. 
Treatment of cancer was curative in all 4 cases. Three patients with T3N0M0 cancer 
had only curative surgical resection and one patient with T3N1M0 cancer had both 
surgical resection and postoperative chemotherapy. After a median follow-up of 4.1 
[1.4-7.3] years, one UC patient died of rectal adenocarcinoma, 2.7 years after 
colectomy with diagnosis of LGD complicating stricture. 3 CD and 1 IBD-U patients 
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without dysplasia or cancer on surgical resected specimen were diagnosed with 
cancer after a median time of 11 [10.5-11.5] years and one died of colorectal cancer 
during follow-up. 
Associated factors to dysplasia or cancer  
In univariate analysis, age at stricture diagnosis (OR, 95%CI; 1.04 [1.004-1.08], 
p=0.03) and the presence of no active disease at time of surgery (OR, 5.63; [1.43-
22.12], p=0.01) were significantly associated to dysplasia or cancer on colonic 
stricture. In multivariate analysis, only the presence of no active disease at time of 
surgery was associated to dysplasia or cancer (OR, 4.86; [1.11-21.27], p=0.036).  
We evaluated the prevalence of primary sclerosing cholangitis (PSC) in 64 included 
patients by 4 centers. Among them, only 2 patients had PSC and 2 patients had 
colonic dysplasia. Among them, one patient had both low-grade dysplasia and PSC. 
The low prevalence of PSC did not allow us to search for statistical association 
between PSC and dysplasia/cancer on colonic stricture.  
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Discussion 
 The management of IBD patients with colonic stricture(s) remains a challenge 
in clinical practice. We report here the largest study evaluating the risk of dysplasia or 
cancer complicating colonic strictures in IBD. More than 12,000 IBD patients 
operated on for IBD between 1992 and 2014 were screened to identify 293 patients 
operated on for colonic strictures. Importantly, only strictures without dysplasia or 
cancer known at the time of surgery were included.  
In case of cancer or high-grade dysplasia on colonic stricture, the decision must be 
the surgical resection (16, 17). In the absence dysplasia or cancer on stricture 
endoscopic biopsies, the best therapeutic option remains debated. Colonoscopy 
biopsies cannot rule out dysplasia or cancer on the stricture (10). Rutter at al. had 
shown that up to 30% of strictures initially considered as benign after endoscopic 
biopsies, were later discovered to have cancer in the stricture (10). The fear of 
missed associated colorectal cancer leads frequently to colonic resection. However, 
therapeutic decisions are taken from data coming from old studies published before 
the 90’s, which included a low number of patients (7, 8, 9, 10, 12, 14). 
Colorectal cancer was observed in 0.8% of CD patients and 5% of UC patients of our 
cohort of IBD patients.  To our knowledge, only one study had evaluated the risk of 
colorectal cancer complicating stricture in CD (12); 7% (9/132) of patients with 
colonic stricture had cancer. Five studies had evaluated the risk of cancer 
complicating colonic strictures in UC; this risk ranged from 0 to 33% (7, 8, 9, 12, 14). 
In our study, high grade or low grade dysplasia was observed in 2.5% of UC patients.  
One study evaluated the risk of dysplasia complicating strictures in UC, which was 
observed in 11 of 15 (73%) of patients (7).  
We observed high grade and low grade dysplasia in respectively 0.4% and 1.2% of 
CD patients. Hence, the risk of both dysplasia and cancer was lower in CD than in 
UC. High-grade dysplasia or colorectal adenocarcinoma was observed in 7.5% of 
resected strictures in UC. Colonic strictures are known to be less frequent in UC than 
in CD, but their occurrence in UC should systematically raise concerns about cancer.  
We also looked at factors associated with dysplasia or cancer on stricture. No active 
disease at surgery according to physician judgement was the only factor associated 
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to dysplasia/cancer on stricture identified in multivariate analysis. Factors associated 
with dysplasia or cancer on colonic strictures remain poorly investigated. Gumaste et 
al. have identified disease duration, proximal location of stricture and obstructive 
symptom as associated factors to dysplasia in UC (8). In CD, age at stricture 
diagnosis was higher in patients with malignant stricture (12). 
In our study, both age and disease duration at surgery were significantly associated 
to dysplasia/cancer in IBD, but only in univariate analysis. All cancer/dysplasia in UC 
patients developed after more than 15 years of disease evolution and in patients 
older than 60 years. In CD, clinical presentation of patients with dysplasia/cancer 
complicating strictures was more heterogeneous. Age at stricture diagnosis ranged 
from 20 to 70 years in CD, while it ranged from 59 to 65 in UC. Disease duration at 
stricture diagnosis ranged from 0 to 32 years in CD and from 15 to 30 years in UC. 
Stricture duration at surgery was shorter in UC than in CD (p=0.08), probably 
because of the fear of cancer in UC.  
In our study, surgical procedure was different between colonic strictures complicating 
CD or UC. Coloprotectomy was the most frequent surgical procedure in UC while it 
was partial colectomy in CD patients. International guidelines recommend total 
colectomy in case of flat high grade dysplasia complicating UC (18).  In CD, there are 
limited data on the appropriate management of dysplasia. Nearly 50% of CD patients 
who underwent a total coloprotectomy or subtotal colectomy for dysplasia had 
multifocal dysplasia (19) and more than two thirds who had partial colectomy for 
dysplasia or cancer developed new dysplasia or cancer over time (20). All these 
findings suggest that total proctocolectomy should be considered in CD, and 
probably explain that about 50% of CD patients underwent total colectomy or 
coloprotectomy in our study.  
Only few studies evaluated the outcome and prognosis of colonic cancer 
complicating stricture. It was previously reported that strictures associated cancer in 
UC were more aggressive than those do not develop on strictures (8). These results 
were not confirmed in CD (12). No metastatic cancer was observed in our study and 
all patients underwent curative treatment. At the end of follow-up, one patient with 
low-grade dysplasia on stricture died of metachronous colorectal cancer. 
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There are some limitations of our study. First, it is retrospective.  Second, the 
identification of associated factors should be interpreted cautiously due the relatively 
low number of dysplasia/cancer. Disease activity, the only factor associated to 
dysplasia/cancer, was retrospectively and subjectively assessed by the physician. 
Association between PSC and dysplasia/cancer on colonic stricture could not be 
assessed. According to the design of the study, these results were only applicable to 
IBD patients with colonic strictures without dysplasia or cancer on preoperative 
endoscopic biopsies. However there are several strengths. This nationwide study is 
currently the largest one having assessed the risk of dysplasia/cancer on colonic 
stricture in IBD, with the largest number of included strictures. For the first time, only 
strictures without dysplasia or cancer known at the time of surgery were included. 
Finally, to reduce bias related to the denominator, only centers having access to a 
clinical, surgical or pathological database including all consecutive adult patients 
operated on for IBD could participate in this study. 
In conclusion, colorectal strictures represent 2.3% of overall surgery indication in 
IBD. In patients without dysplasia or cancer known on colorectal stricture at the time 
of surgery, cancer or dysplasia was observed in 3.5% of the overall IBD population. 
Cancer was observed in 0.8% of CD and 5% of UC patients. Clinicians have to be 
aware that negative endoscopic biopsy specimens on stricture do not rule out the 
presence of dysplasia or cancer in both CD and UC and surgery should be discussed 
case by case in IBD patients developing colonic stricture, especially in ulcerative 
colitis. 
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Figure Legends: 
Figure 1. Flow chart.  IBD, Inflammatory Bowel Disease; CD, Crohn’s disease; UC, 
Ulcerative colitis. 
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